NEW
YORK, May 21, 2024 /PRNewswire/ -- The
Gross Law Firm issues the following notice to shareholders of
bluebird bio, Inc. (NASDAQ: BLUE).
Shareholders who purchased shares of BLUE during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4
CLASS PERIOD: April 24,
2023 to December 8, 2023
ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food
and Drug Administration (FDA) approved its drug Lyfgenia
(lovotibeglogene autotemcel), also known as lovo-cel for the
treatment of sickle cell disease in patients ages 12 and older who
have a history of vaso-occlusive events (VOEs). However, the
Lyfgenia approval came with a black box warning for haematological
malignancies after two patients developed AML during the clinical
trials. Analysts noted that they did not expect the black box
warning or the absence of a priority review voucher. Following this
news, Blue's stock price fell by $1.95 per share, or approximately 40% to close at
$2.86 per share.
DEADLINE: May 28, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of BLUE during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is May 28, 2024. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/investors-in-bluebird-bio-inc-should-contact-the-gross-law-firm-before-may-28-2024-to-discuss-your-rights--blue-302150544.html
SOURCE The Gross Law Firm